EGFR and metastatic colorectal cancer: While anti-EGFR therapy was associated with a higher likelihood of tumor fibrosis ≥40% compared to anti-VEGF therapy, this did not result in improved overall survival among patients undergoing resection of hepatic M1 metastases from metastatic colorectal cancer (mCRC).